LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended ...

Billionaire Stephen Ross’ company buys Broward office for $37 million Nonprofit to lay off 53, close facility after loss of ...

On Carilion Clinic announced the installation of Usability Works, a biotechnology engineering consultancy. As a part of ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript March 30, 2026 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.2.

MANHATTAN BEACH, CA, UNITED STATES, April 3, 2026 /EINPresswire.com/ -- Driving Innovation and Growth in Biotechnology ...

XBI has nearly 50 points of upside to reach its previous all-time high, and 2026 biotech industry conditions may help it get ...

Cancer treatment has long been haunted by the same problem: how do you strike dangerous cells without hitting healthy ones ...

Moby summary of PDS Biotechnology Corporation's Q4 2025 earnings call ...

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

LIXTE Biotechnology Holdings, Inc. ('LIXTE” or the 'Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech ...

PDS Biotechnology Corporation (PDSB) on Monday reported a loss of $7.6 million in its fourth quarter. The East Princeton, New Jersey-based company said it had a loss of 14 cents per share. For the ...

As the Trump administration cracks down on the H-1B visa program, which allows skilled workers like software engineers to ...